Biopharmaceutics & Drug disPosition

Papers
(The TQCC of Biopharmaceutics & Drug disPosition is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
21
In situ evaluation of the impact of metformin or verapamil coadministration with vildagliptin on its regional absorption from the rabbit’s intestine17
16
Absorption, metabolism, and pharmacokinetic profile of xanthohumol in rats as determined via UPLC‐MS/MS14
Decreased plasma acetaminophen glucuronide/acetaminophen concentration ratio warns the onset of acetaminophen‐induced liver injury14
Aging and brain free cholesterol concentration on amyloid‐β peptide accumulation in guinea pigs12
Evaluation of bottom‐up modeling of the blood–brain barrier to improve brain penetration prediction via physiologically based pharmacokinetic modeling11
Issue Information10
9
Evaluating gender effect in the generic bioequivalence studies by physiologically based pharmacokinetic modeling – A case study of dextromethorphan modified release tablets9
Self‐micellizing solid dispersion of tacrolimus: Physicochemical and pharmacokinetic characterization9
Issue Information8
Evaluation of sex differences in the pharmacokinetics of oral sumatriptan in healthy Korean subjects using population pharmacokinetic modeling8
Issue Information8
Attenuation of phenobarbital‐induced cytochrome P450 expression in carbon tetrachloride‐induced hepatitis in mice models7
Issue Information7
Issue Information7
Utility of cystatin C and serum creatinine‐based glomerular filtration rate equations in predicting vancomycin clearance: A population pharmacokinetics analysis in elderly Chinese patients7
Evidence for cytochrome P450 3A4‐mediated metabolic activation of SCO‐2677
Novel Enteric Microsphere of Beclomethasone Dipropionate With Colon Delivery and Enhancement of Anti‐Inflammatory Effects6
Irinotecan‐induced gastrointestinal damage alters the expression of peptide transporter 1 and absorption of cephalexin in rats6
Metabolism and pharmacokinetic study of deuterated osimertinib6
Physiologically based pharmacokinetic modelling of acetaminophen in preterm neonates—The impact of metabolising enzyme ontogeny and reduced cardiac output6
Estimation of fraction of drug metabolism by a single UDP‐glucuronosyl transferase enzyme using relative expression factor6
5
Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3‐selective GABAkine KRM‐II‐815
Species Differences in Carboxylesterases Among Humans, Cynomolgus Monkeys, and Mice in the Hydrolysis of Atorvastatin Derivatives5
Pharmacokinetic control of orally dosed cyclosporine A with mucosal drug delivery system5
Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells5
Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study5
Intestinal absorption pathways of lisinopril: Mechanistic investigations4
Involvement of SLC16A1/MCT1 and SLC16A3/MCT4 in l‐lactate transport in the hepatocellular carcinoma cell line4
Identification and characterization of an endogenous biomarker of the renal vectorial transport (OCT2‐MATE1)4
Predicting transporter mediated drug–drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward4
4
Issue Information4
Integration of artificial neural network and physiologically based biopharmaceutic models in the development of sustained‐release formulations4
Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds4
Prediction of basic drug exposure in milk using a lactation model algorithm integrated within a physiologically based pharmacokinetic model4
0.098833084106445